Objective: To explore the implications of the perimenopause awareness movement and its impact on women's health perceptions. Key Findings: Perimenopause is ofte
Objective: To assess the quality and reliability of YouTube videos related to oral hygiene uploaded between February 2020 and February 2023. Key Findings: 76% o
Objective: To explore medical screenings and treatments that may be unnecessary for older adults, based on recent research. Key Findings: The benefits of repeat
Objective: To assess perceptions of gender discrimination among surgeons in the Anglophone Caribbean. Key Findings: 64% of respondents observed discrimination a
Objective: To analyze the long-term outcomes of patients with rheumatoid arthritis (RA) in the KURAMA cohort over a 10-year period. Key Findings: Include detail
Objective: To report early postoperative outcomes of two patients with rotary tiller-related traumatic knee dislocation and multiligament rupture, highlighting
Objective: To evaluate sex disparities in cystic fibrosis (CF) outcomes before and after the introduction of highly effective modulator therapy. Key Findings: F
Objective: To evaluate the efficacy of Janus kinase inhibitors (JAKi) monotherapy in patients with rheumatoid arthritis compared to methotrexate or placebo. Key
Objective: Revise to ensure it directly reflects the source material. Key Findings: Rephrase to ensure they are directly sourced from the context. Interpretatio
Objective: To explore the role of liquid biopsy comprehensive genomic profiling (CGP) in enhancing precision oncology, particularly in lung and breast cancer, a
Liquid biopsy comprehensive genomic profiling (CGP) enhances precision oncology by providing earlier insights and faster access to targeted therapies.
Liquid biopsy offers a non-invasive alternative to tissue testing, addressing limitations in obtaining sufficient tumor samples for genomic profiling.
ctDNA analysis captures tumor heterogeneity and resistance mechanisms, providing a broader view than single tissue biopsies for treatment decisions.
Integrating liquid biopsy into lung cancer pathways significantly reduces turnaround times for actionable results and accelerates treatment allocation.
In breast cancer, ctDNA testing for ESR1 mutations demonstrates rapid results and the ability to detect low-frequency variants, aiding therapy guidance.
Objective: To understand the threat posed by hantaviruses to humans following a recent outbreak on a Dutch cruise ship. Key Findings: Rodents are the likely ori
Objective: To develop a modified CRISPR–Cas12a system using DNA guides for RNA detection and cutting. Key Findings: The DNA-guided Cas12a system accurately reco
Objective: To determine if reducing music volume in group fitness classes affects perceived exercise intensity, specifically hypothesizing that lower volumes wo
Objective: To discuss the implications and limitations of a new vibe-coded proteomics data analysis application developed by Jesse Meyer, as reported in The Ana
Objective: To improve understanding of diabetic macular edema (DME) and encourage earlier engagement with eye care, particularly among underserved communities,
Objective: To investigate the potential of delivering a neuroprotective retinal therapy via eye drops instead of injections. Key Findings: Topical JGRi1 reached
Objective: To highlight the contributions of Tao Chen in pharmaceutical analytical science and her insights on the industry's evolution. Key Findings: Analytica
Tao Chen is a pharmaceutical analytical scientist at Genentech, focusing on analytical chemistry and therapeutic modalities.
Chen was featured in The Analytical Scientist’s 2022 Top 40 Under 40 Power List and received the 2024 Enabling Technologies Consortium Recognition Award.
Analytical science is essential in drug development, guiding processes from API development to regulatory filings and ensuring patient safety.
Challenges in analytical science include developing robust methods for complex modalities and integrating automation and AI into workflows.
Advancements in instrumentation and data analysis are crucial for adapting analytical science to meet the needs of complex therapeutic modalities.
Objective: To compare acute and early late toxicity in patients with prostate cancer treated with moderately hypofractionated radiotherapy versus those treated
Prostate cancer is the most commonly diagnosed malignancy among men in Colombia, highlighting a significant public health burden.
A study compared acute and late toxicity in prostate cancer patients treated with moderately hypofractionated versus ultra-hypofractionated radiotherapy.
Acute toxicity was significantly higher in the moderately hypofractionated group compared to the ultra-hypofractionated group (25.17% vs. 11.63%; p=0.013).
Late toxicity was also more frequent in the moderately hypofractionated group, with erectile dysfunction being the most common late event.
Ultra-hypofractionated radiotherapy demonstrated a favorable safety profile, associated with lower odds of acute toxicity compared to moderately hypofractionated radiotherapy.